|
1
|
Peyromaure EM, Mao K, Sun Y, Xia S, Jiang
N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of
prostate cancer detection and management in China and in France.
Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu D, Zhou Y, Pan H, Qu P and Zhou J:
MicroRNA99a inhibits cell proliferation, colony formation ability,
migration and invasion by targeting fibroblast growth factor
receptor 3 in prostate cancer. Mol Med Rep. 11:1469–1475. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rubin MA, Maher CA and Chinnaiyan AM:
Common gene rearrangements in prostate cancer. J Clin Oncol.
29:3659–3668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng X, He G, Liu J, Luo F, Peng X, Tang
S, Gao Z, Lin Q, Keller JM, Yang T and Keller ET: Recent advances
in bone-targeted therapies of metastatic prostate cancer. Cancer
Treat Rev. 40:730–738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Souza AG, Bastos VAF, Silva IBB, Marangoni
K and Goulart VA: Different gene therapy strategies: A overview for
prostate cancer. Curr Gene Ther. 16:287–291. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koupparis A and Gleave ME: Multimodal
approaches to high-risk prostate cancer. Curr Oncol. 17 Suppl
2:S33–S37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee YS and Dutta A: MicroRNAs: Small but
potent oncogenes or tumor suppressors. Curr Opin Investig Drugs.
7:560–564. 2006.PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fazi F and Blandino G: MicroRNAs: Non
coding pleiotropic factors in development, cancer prevention and
treatment. Microrna. 2:812013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Massillo C, Dalton GN, Farré PL, De Luca P
and De Siervi A: Implications of microRNA dysregulation in the
development of prostate cancer. Reproduction. 154:R81–R97. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spizzo R, Nicoloso MS, Croce CM and Calin
GA: SnapShot: MicroRNAs in cancer. Cell. 137:586. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng J, Ge P, Liu X, Wei J, Wu G and Li
X: miR-136 inhibits gastric cancer-specific peritoneal metastasis
by targeting HOXC10. Tumour Biol. 39:10104283177062072017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan M, Li X, Tong D, Han C, Zhao R, He Y
and Jin X: miR-136 suppresses tumor invasion and metastasis by
targeting RASAL2 in triple-negative breast cancer. Oncol Rep.
36:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu
Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin
chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pavese JM, Ogden IM, Voll EA, Huang X, Xu
L, Jovanovic B and Bergan RC: Mitogen-activated protein kinase
kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS
One. 9:e1022892014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wan X, Huang W, Yang S, Zhang Y, Zhang P,
Kong Z, Li T, Wu H, Jing F and Li Y: Androgen-induced miR-27A acted
as a tumor suppressor by targeting MAP2K4 and mediated prostate
cancer progression. Int J Biochem Cell Biol. 79:249–260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lotan TL, Lyon M, Huo D, Taxy JB, Brendler
C, Foster BA, Stadler W and Rinker-Schaeffer CW: Up-regulation of
MKK4, MKK6 and MKK7 during prostate cancer progression: An
important role for SAPK signalling in prostatic neoplasia. J
Pathol. 212:386–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Jia X, Hou L and Liu X: Screening
of differently expressed miRNA and mRNA in prostate cancer by
integrated analysis of transcription data. Urology. 94:313.e1–e6.
2016. View Article : Google Scholar
|
|
26
|
Wang Z, Xu L, Hu Y, Huang Y, Zhang Y,
Zheng X, Wang S, Wang Y, Yu Y, Zhang M, et al: miRNA let-7b
modulates macrophage polarization and enhances tumor-associated
macrophages to promote angiogenesis and mobility in prostate
cancer. Sci Rep. 6:256022016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li JZ, Li J, Wang HQ, Li X, Wen B and Wang
YJ: miR-141-3p promotes prostate cancer cell proliferation through
inhibiting kruppel-like factor-9 expression. Biochem Biophys Res
Commun. 482:1381–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeong JY, Kang H, Kim TH, Kim G, Heo JH,
Kwon AY, Kim S, Jung SG and An HJ: MicroRNA-136 inhibits cancer
stem cell activity and enhances the anti-tumor effect of paclitaxel
against chemoresistant ovarian cancer cells by targeting Notch3.
Cancer Lett. 386:168–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan Q, Cao G, Li J, Zhang Y and Yang W:
MicroRNA-136 inhibits colon cancer cell proliferation and invasion
through targeting liver receptor homolog-1/Wnt signaling. Gene.
628:48–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and
Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation,
apoptosis, and epithelial-mesenchymal transition by targetting PMEL
through the Wnt signaling pathway. Biosci Rep. 37:BSR201707432017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen S, Yue H, Li Y, Qin J, Li K, Liu Y
and Wang J: Upregulation of miR-136 in human non-small cell lung
cancer cells promotes Erk1/2 activation by targeting PPP2R2A.
Tumour Biol. 35:631–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J
and Li M: MiR-136 promotes apoptosis of glioma cells by targeting
AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu H, Liu Q, Cai T, Chen YD, Liao F and
Wang ZF: MiR-136 modulates glioma cell sensitivity to temozolomide
by targeting astrocyte elevated gene-1. Diagn Pathol. 9:1732014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo
G, Jiang J and Cui S: Expression of miR-136 is associated with the
primary cisplatin resistance of human epithelial ovarian cancer.
Oncol Rep. 33:591–598. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshida BA, Dubauskas Z, Chekmareva MA,
Christiano TR, Stadler WM and Rinker-Schaeffer CW:
Mitogen-activated protein kinase kinase 4/stress-activated
protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis
suppressor gene encoded by human chromosome 17. Cancer Res.
59:5483–5487. 1999.PubMed/NCBI
|
|
36
|
Tesser-Gamba F, Petrilli AS, de Seixas
Alves MT, Filho RJ, Juliano Y and Toledo SR: MAPK7 and MAP2K4 as
prognostic markers in osteosarcoma. Hum Pathol. 43:994–1002. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu X, Gong Z, Sun L, Ma L and Wang Q:
MicroRNA-802 plays a tumour suppressive role in tongue squamous
cell carcinoma through directly targeting MAP2K4. Cell Prolif.
50:2017. View Article : Google Scholar
|
|
38
|
Liu S, Liu YY and Li R: Expressions of
MAP2K4 and estrogen receptor and their clinical significance in
invasive breast cancer. Nan Fang Yi Ke Da Xue Xue Bao. 37:488–493.
2016.(In Chinese). PubMed/NCBI
|
|
39
|
Wang L, Pan Y and Dai JL: Evidence of MKK4
pro-oncogenic activity in breast and pancreatic tumors. Oncogene.
23:5978–5985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yeasmin S, Nakayama K, Rahman MT, Rahman
M, Ishikawa M, Katagiri A, Iida K, Nakayama N and Miyazaki K: MKK4
acts as a potential tumor suppressor in ovarian cancer. Tumour
Biol. 32:661–670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ishikawa M, Nakayama K, Rahman MT, Rahman
M, Katagiri A, Iida K and Miyazaki K: Functional and
clinicopathological analysis of loss of MKK4–– expression in
endometrial cancer. Oncology. 79:238–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
